The effects of use of medications on striatal dopamine transporter binding assessed by [123I]I-FP-CIT SPECT in patients with Parkinson’s disease from the PPMI cohort
- 1Department of Radiology and Nuclear Medicine, University of Amsterdam, Amsterdam UMC, Meibergdreef 9, Amsterdam, 1105 AZ The Netherlands
- 2Department of Pharmacy, University of Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands
Abstract
Purpose: Several centrally acting medications may interfere with dopamine transporter (DAT) imaging using [¹²³I]I-FP-CIT SPECT, potentially leading to misinterpretation. We therefore evaluated the effects of several medications on striatal DAT binding assessed by [123I]I-FP-CIT SPECT in patients with Parkinson’s disease (PD).
Methods: Data were obtained from the Parkinson’s Progression Markers Initiative (PPMI). PD patients with abnormal [¹²³I]I-FP-CIT SPECT scans, and available medication and clinical data, were included. The effects of bupropion, venlafaxine, methylphenidate, modafinil, and codeine were assessed. Striatal specific binding ratios (SBRs) of the caudate nucleus and putamen were analysed using multivariable linear regression models adjusted for relevant covariates.
Results: Data from 752 PD patients were included. Use of the evaluated medications was associated with lower SBRs in the ipsilateral and contralateral caudate nucleus (-13.5% and -13.7%, respectively) and putamen (-6.5% and -8.2%, respectively; all p < 0.01). Medication-specific analyses showed the largest reductions for methylphenidate and modafinil, with relative reductions in caudate nucleus SBRs of up to -33.2% and -25.5%, respectively (both p < 0.01). In contrast, bupropion and venlafaxine were associated with smaller, but still significant, reductions, whereas no significant associations were observed for codeine.
Conclusion: Use of methylphenidate and modafinil in particular is associated with significantly reduced striatal [¹²³I]I-FP-CIT binding in PD patients. Medication use should be carefully considered when interpreting DAT SPECT scans. Temporary discontinuation may be considered in selected cases when clinically appropriate.
Related
- Selective Dopamine Transporter Inhibitor CE-123 Modulates Region-Specific Intestinal Mucosal and Immune Responses Following Fear Conditioning and Extinction in Adolescent Female Rats
- Striatal M4 Receptors Mediate M4 PAM Antipsychotic-like Efficacy Independently of Normalizing Striatal Dopamine Release
- D2 dopamine and CB2 cannabinoid receptor cooperation restores striatal LTP in an epilepsy model
- Psychiatric and Behavioral Adverse Event Reporting Patterns Among Dopamine Agonists in Parkinson’s Disease Using the Food and Drug Administration Adverse Event Reporting System
- Dopaminergic therapy selectively amplifies hallucination susceptibility in patients with Parkinson's disease with cortico-striatal hyperconnectivity
BibTeX
@article{ali2026effects,
title = {{The effects of use of medications on striatal dopamine transporter binding assessed by [123I]I-FP-CIT SPECT in patients with Parkinson’s disease from the PPMI cohort}},
author = {Abdallah Nour Ali and Ilham Malik and Jan Booij and Youssef Chahid},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
month = aug,
doi = {10.1007/s00259-026-08136-2},
url = {https://doi.org/10.1007/s00259-026-08136-2},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - The effects of use of medications on striatal dopamine transporter binding assessed by [123I]I-FP-CIT SPECT in patients with Parkinson’s disease from the PPMI cohort
AU - Abdallah Nour Ali
AU - Ilham Malik
AU - Jan Booij
AU - Youssef Chahid
PY - 2026
DA - 2026/08/15
JO - European Journal of Nuclear Medicine and Molecular Imaging
DO - 10.1007/s00259-026-08136-2
UR - https://doi.org/10.1007/s00259-026-08136-2
AB - Purpose: Several centrally acting medications may interfere with dopamine transporter (DAT) imaging using [¹²³I]I-FP-CIT SPECT, potentially leading to misinterpretation. We therefore evaluated the effects of several medications on striatal DAT binding assessed by [123I]I-FP-CIT SPECT in patients with Parkinson’s disease (PD). Methods: Data were obtained from the Parkinson’s Progression Markers Initiative (PPMI). PD patients with abnormal [¹²³I]I-FP-CIT SPECT scans, and available medication and clinical data, were included. The effects of bupropion, venlafaxine, methylphenidate, modafinil, and codeine were assessed. Striatal specific binding ratios (SBRs) of the caudate nucleus and putamen were analysed using multivariable linear regression models adjusted for relevant covariates. Results: Data from 752 PD patients were included. Use of the evaluated medications was associated with lower SBRs in the ipsilateral and contralateral caudate nucleus (-13.5% and -13.7%, respectively) and putamen (-6.5% and -8.2%, respectively; all p < 0.01). Medication-specific analyses showed the largest reductions for methylphenidate and modafinil, with relative reductions in caudate nucleus SBRs of up to -33.2% and -25.5%, respectively (both p < 0.01). In contrast, bupropion and venlafaxine were associated with smaller, but still significant, reductions, whereas no significant associations were observed for codeine. Conclusion: Use of methylphenidate and modafinil in particular is associated with significantly reduced striatal [¹²³I]I-FP-CIT binding in PD patients. Medication use should be carefully considered when interpreting DAT SPECT scans. Temporary discontinuation may be considered in selected cases when clinically appropriate.
SN - 1619-7070
SN - 1619-7089
ER -